Clinical Trial Update: A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating XP23829 in adults with moderate-to-severe chronic plaque psoriasis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• XP23829

Snippet

Sponsor: Dr. Reddy's Laboratories Limited | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2022-04-12